Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis
Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output.
Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement.
Atherosclerosis is a vascular disease, in which the blood vessels are narrowed or clogged due to plaque made up of fat, cholesterol, immune cells and vascular wall cells in the blood vessel. This results in ischemic heart diseases (e.g., myocardial infarction and angina), stroke and peripheral arterial disease. Ischemic heart disease and stroke are the world's leading causes of death, accounting for a combined 15.2 million deaths worldwide in 2016.1
Statins2 that lower cholesterol and lipid levels in blood are widely used to alleviate the onset and progression of atherosclerosis. Despite the success of lipid lowering drugs, atherosclerotic diseases continue to be the major cause of death worldwide. This highlights the need to develop new drugs that can complement the lipid lowering drugs by targeting new mechanisms of action to prevent and reduce the risk of atherosclerotic diseases.
“We are delighted to cooperate with the internationally renowned research team at Emory University led by Dr. Hanjoong Jo, John and Jan Portman Endowed Professor and Associate Chair in the Department of Biomedical Engineering and the Division of Cardiology, who is a leader in the area of mechanically regulated genes in atherosclerosis research,” says the official of Celltrion. “Based on this Incubation agreement, Celltrion will make further plans to secure more various new drugs and technologies. We are hoping that more research institutes and corporations will take an interest in our open innovation.”
Meanwhile, Celltrion recently announced a plan of launching Bio CDMO (Contract Development and Manufacturing Organization) business, in a bid to pursue open innovation for development of new drugs.
top 10 causes of death
2 Cholesterol synthesis inhibitor; the drugs are said to be taken daily by over 30 million people worldwide for the treatment of high blood cholesterol.
About Celltrion, Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
DAWEX23.5.2019 08:47:03 CEST | Pressemeddelelse
Dawex Raises €5 Million to Accelerate the Development of the Data Economy
TTS-PHARMA-LIMITED23.5.2019 08:02:11 CEST | Pressemeddelelse
TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment
CHINA-YIWU-FAIR23.5.2019 06:48:09 CEST | Pressemeddelelse
Buy and Sell Globally: 2019 Yiwu Imported Commodities Fair Opens in “World’s Capital of Small Commodities”
NC-LENOVO-NCTA23.5.2019 06:29:12 CEST | Pressemeddelelse
Lenovo Achieves Record Revenue for FY18/19 Driven by Success of Intelligent Transformation Strategy and Strong Operational Performance
HONG-KONG-TRADE-DEVELOP23.5.2019 03:46:10 CEST | Pressemeddelelse
The 26th HKTDC Hong Kong Fashion Week for Spring/Summer Opens in July
CQN-PRAXIDIA-KNOWLEDGE22.5.2019 20:10:07 CEST | Pressemeddelelse
CORRECTING AND REPLACING Teleperformance Groups ‘Praxidia Knowledge Services’ partners with CallMiner to launch TP Interact – a Comprehensive Interaction Analytics Solution
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum